Ambryon Biosciences

A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease

Phase 2/3 single-arm trial of exagamglogene autotemcel (exa-cel), autologous CD34+ cells CRISPR-Cas9 edited at the BCL11A enhancer, in patients aged 12 to 35 with severe sickle cell disease. 29 of 30 evaluable patients had no severe vaso-occlusive crisis for 12 months or more.

StatusCompleted
PhasePhase 2 3
Primary Endpoint ResultMet
Enrollment63
Start Date2018-11-27
Primary Completion Date2025-07-07

Results Summary

In the phase 3 primary analysis (NEJM 2024; June 2023 data cut; 44 patients treated), 29 of 30 evaluable patients (97%; 95% CI 83 to 100) had no severe vaso-occlusive crisis for at least 12 consecutive months (P<0.001 against a 50% null response), and 30 of 30 had no hospitalization for such crises for 12 months. Neutrophils and platelets engrafted in all patients (median 27 and 35 days). Mean HbF was 36.9% of total hemoglobin at month 3 and at least 40% from month 6. Posted final results (46 treated): 91.3% (95% CI 79.2 to 97.6) met the 12-month crisis-free endpoint; mean annualized red-cell units transfused after month 12 was 0 (n=45). Grade 3 or 4 adverse events occurred in 42 of 44 (paper), mostly from busulfan (stomatitis 55%, febrile neutropenia 48%); serious events in 22 of 46 (posted), none judged related to exa-cel (paper). No graft failure or cancer. One patient died of SARS-CoV-2 respiratory failure 268 days after infusion.

Design Implications

Editing the erythroid-specific BCL11A enhancer, rather than the coding sequence, raised HbF to at least 40% of total hemoglobin and stopped severe crises in nearly all evaluable patients, supporting lineage-restricted knockdown of a fetal-hemoglobin repressor as a mutation-independent route for sickle cell disease and beta-thalassemia. Benefit accompanied at least 70% edited alleles in blood and about 86% in bone marrow CD34+ cells, a benchmark for editing depth. The safety burden came from myeloablative busulfan (grade 3 or 4 events in 95%, one death with busulfan-associated lung injury) and repeated plerixafor mobilization (median 2 cycles, up to 6), not from the edit; 17 of 63 enrolled patients were never dosed. Gentler conditioning or in vivo editing of stem cells would widen eligibility. Patients with crises after infusion had HbF and editing similar to responders, so non-HbF causes (infection, chronic pain, organ damage) still need adjudication.

Rationale

Exagamglogene autotemcel (exa-cel, CTX001) is autologous CD34+ hematopoietic stem and progenitor cells edited ex vivo with CRISPR-Cas9 and a single-guide RNA at the erythroid-specific enhancer of BCL11A, a transcription factor that represses fetal hemoglobin (HbF) after birth. Disrupting the enhancer lowers BCL11A only in the erythroid lineage, so red cells make HbF again. HbF does not polymerize with sickle hemoglobin, and people with sickle cell disease who inherit persistent HbF have few or no symptoms. Raising HbF and total hemoglobin was therefore expected to eliminate vaso-occlusive crises. Patients receive busulfan myeloablation before the infusion.

Limitations

Single-arm, open-label trial with no concurrent control; efficacy is judged against a 50% null response and each patient's own crisis history. The paper's primary analysis is an interim cut (30 evaluable of 44 treated), and the posted final results (46 treated) give 91.3% rather than 97%. Only 46 of 63 enrolled patients were infused. Ages 12 to 35 only; follow-up is 2 years per patient. The registry lists phase 2/3, but the official title says phase 1/2/3.

Registry record

This is a single-arm, open-label, multi-site, single-dose Phase 1/2/3 study in participants with severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) using CTX001.

Primary OutcomesPercentage of Participants Who Have Not Experienced Any Severe Vaso-occlusive Crisis (VOC) for at Least 12 Consecutive Months (VF12) After Exa-cel Infusion, Percentage of Participants Who Achieve Neutrophil Engraftment, Time to Neutrophil Engraftment for Participants Who Achieve Neutrophil Engraftment, Time to Platelet Engraftment for Participants Who Achieve Platelet Engraftment, Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Transplant-related Mortality (TRM) Within 100 Days After Exa-cel Infusion, Transplant-related Mortality Within 12 Months Post Exa-cel Infusion, All-cause Mortality
Registry Last Updated2026-09-16
Results First Posted Date2026-09-16
Minimum Age12 Years
Modalitiesgene_editing, cell_therapy
Maximum Age35 Years
Intervention NamesExa-cel, Exagamglogene autotemcel, CTX001
AllocationNot Applicable
MaskingNone
Primary PurposeTreatment
Has ResultsYes
Enrollment TypeActual
CountriesUnited States, Belgium, Canada, France, Germany, Italy, United Kingdom
Intervention Typesbiological
Study TypeInterventional
Intervention ModelSingle Group
Healthy VolunteersNo
Condition TermsSickle Cell Disease, Hematological Diseases, Hemoglobinopathies, Anemia, Sickle Cell, Hematologic Diseases
Completion Date2025-07-07
Lead Sponsor ClassIndustry
Eligibility SexAll

Official Title

A Phase 1/2/3 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Severe Sickle Cell Disease

Eligibility Criteria

Key Inclusion Criteria:

  • Diagnosis of severe sickle cell disease as defined by:
  • Documented severe sickle cell disease genotype
  • History of at least two severe vaso-occlusive crisis events per year for the previous two years prior to enrollment
  • Eligible for autologous stem cell transplant as per investigators judgment

Key Exclusion Criteria:

  • An available 10/10 human leukocyte antigen (HLA)-matched related donor
  • Prior hematopoietic stem cell transplant (HSCT)
  • Clinically significant and active bacterial, viral, fungal, or parasitic infection

Other protocol defined inclusion/exclusion criteria may apply.

Identifiers & revision